The pharmacologic treatment options for chemotherapy-induced peripheral neuropathy (CIPN) including topical agents, tricyclic antidepressants, and anticonvulsants have shown limited efficacy. Opioids are highly effective against cancer-related pain. Among opioids, oxycodone has favorable analgesic potency against neuropathic pain because of its high affinity to kappa receptor. Therefore, we investigated the efficacy and safety of oxycodone/naloxone in CIPN patients not adequately controlled with anticonvulsants in Korea.
Medical Affairs, Mundipharma Korea, Seoul, KOREA Aim: The pharmacologic treatment options for chemotherapy-induced peripheral neuropathy (CIPN) including topical agents, tricyclic antidepressants, and anticonvulsants have shown limited efficacy. Opioids are highly effective against cancer-related pain. Among opioids, oxycodone has favorable analgesic potency against neuropathic pain because of its high affinity to kappa receptor. Therefore, we investigated the efficacy and safety of oxycodone/naloxone in CIPN patients not adequately controlled with anticonvulsants in Korea.
Methods:
The patients with CIPN not adequately controlled with pregabalin or gabapentin were enrolled (Numeric Rating Scale 0-10; NRS score ≥4 at baseline). The use of weak opioids, NSAIDs or acetaminophen was also permitted before and during the study. In addition to pregabalin or gabapentin of the existing dosages, oxycodone/ naloxone was started with 20/10 mg/day, then up-titrated to 80/40 mg/day at the discretion of investigators. The primary outcome was the difference in NRS score at 4 weeks from baseline. Patient-reported neuropathic symptoms were evaluated with the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group/ Neurotoxicity (FACT/GOG-Ntx) questionnaire as the secondary outcome. Results: Total 73 patients were enrolled and 72 were included in the safety set and 66 in full analysis set. The mean daily dose of pregabalin and gabapentin was 304.1 ± 24.7 mg (n = 37) and 1091.6 ± 337.3 mg (n = 37), respectively. The mean daily dose of oxycodone was 23.3 ± 7.5 mg. The baseline mean NRS score was 6.0 ± 1.3 which was reduced to 4.7 ± 2.1 at 4 weeks (difference; -1.3 ± 1.8, p < 0.0001). 43.9% of patients reported a drop in NRS ≥2 after addition of oxycodone/naloxone. The results of FACT/GOG-Ntx showed that the numbness or tingling of hands (Ntx 1) and that of feet (Ntx 2) were improved at 4 weeks ( p = 0.0427, p < 0.0001, respectively). Total 48 adverse drug reactions (ADRs) were reported in 25 patients (34.7%) and common ADRs were dizziness (20.8%) and nausea (9.7%).
Conclusions: The addition of oxycodone/naloxone in CIPN patients not adequately controlled with pregabalin or gabapentin provided additional pain relief and neuropathic symptom control. 
